Comments
A formulation manufacturing facility of Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, received a warning letter from the US Food and Drug Regulator (USFDA).
The Hyderabad-based Aurobindo, earlier said, the unit III received Official Action Indicated (OAI) status by the US FDA.
“Subsequent to OAI, the unit has received a warning letter. There is no impact on the existing supplies to the US markets. The company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.,’‘ it informed the BSE on Friday.
Aurobindo Pharma’s scrip declined 1.91 per cent on the BSE on Friday and is trading at ₹1,490.20 by noon.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.